Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It could also work the other way as well, right? Were the PPS sky rockets?
It happens with stocks sometimes- pps’s go up and down. And with $GBSXD the moves will be extreme considering the size of the float. Float is most likely only 170k or less.
Why is this down 30%? We were on a roll. Did I miss something?
waiting-> http://marizyme.com/ $GBSXD
$300pps Is not a pps prediction-I should have made that clear in my post. the $300pps is the # that came up when I used my standard stock pricing estimation model. Given the likelihood that $GBSXD will generate $6bil a year - the chances of $GBSXD hitting $300 pps are near zero. Butt what the pps estimation shows is that $GBSXD is potentially severely undervalued currently- if the company can produce revenue even at fraction of what they estimate their products market potential is - am willing to take $10+ pps if Marizyme can get their sales in the $100m area.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142627542
FOH with that BS share price prediction
$300 PPS estimation for $GBSXD - see below:
after r/s - o/s is approximately 1m shares
Lots of times these companies only want legacy holders to own 5%
If the above holds true - the o/s would be 20m shares
Revenue of $6bil a year - with a 10% profit margin would = $600m yearly profit
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142530837
$600m profit / 20m shares = $30 EPS
EPS x a factor of 10 = $300 pps
If the below happens $GBSXD could see huge PPS gains:
Marizyme intends to apply for a Rare Pediatric Voucher and
complete studies for application of Krillase in children. The Rare Pediatric Disease Voucher is transferable and of the 13 or so that have been issued most have been sold to large pharmaceutical companies for $125M to $350M.
Total market size in Germany could be as much as $6 Billion for Krillase.
Good day - made over $3 on the ask side. $GBSXD
$GBSXD looking good. upward and onward $$$
Bid/Ask keep moving up!$!$!$!$
$$$$$$$$GBSX (@ 1.05 now)$$$$$$$$$$
Marizyme intends to apply for a Rare Pediatric Voucher and
complete studies for application of Krillase in children. The Rare Pediatric Disease Voucher is transferable and of the 13 or so that have been issued most have been sold to large pharmaceutical companies for $125M to $350M. We intend to complete a pediatric stroke study and license Krillase to Roche/Genentech for human use and then sell the Voucher to the highest bidder. $$$ $GBSXD $$$
$GBSXD - BIOTECH MARIZYME - ACTIVE PATENTS / PENDING PATENTS & KRILLASE PRODUCT:
Patents:
Multiple Applications: WO 2008/070698 A1 (June 12, 2008), Also EP2007/086455, US20110135625
Multiple Applications: US 7,947,270 B2 (May 24 2011)
Wound Healing: WO 2013/149809 A1 (October 10, 2013)
Thrombolysis (Pending): EP 15004350.2 (December 4, 2015)
Dental Health: US 12/741,781 (December 30, 2010) Also Published as: WO 2009/060013 A2,A3 and EP
2217266 A2
European Approvals:
TUV: Class III Medical Device for Wound Care (July 11, 2005)
Filing Contacts: Renata Materna, rmaterna@rmc-rheinfelden.de
2. Krillase® Applications
A. Chronic Wound Care:
Chronic non-healing wounds require special care and often last many month and years or may never fully
heal. The increased prevalence of these types of wounds is caused by growth in diabetes and longer lifespans. Many of these wounds can result in amputation if treatments cannot control the growth of necrotic tissue. To treat these wounds often requires grafting which may not be effective if the wound isn’t properly cleansed of necrotic tissue prior to the graft. We estimate grafting is only successful about 35% of the time. Krillase makes grafting possible by achieving up to a 90% efficacy rate for the grafting process. Krillase has achieved Class III Medical Device classification.
Wound Care Monetization Strategy:
We expect to license this application of our technology first. Our partner expects to complete a facility and intends to sell directly to hospitals as part of their grafting programs. The hospitals are reimbursed $8,500 by the insurance companies for the entire grafting procedure and we expect to receive approximately $1,500 per procedure from the hospital leaving $7,000 for the hospital to cover their expenses, the doctors, and profit margins. Total market size in Germany could be as much as $6 Billion for Krillase as a result
B. Thrombolysis:
Krillase will completely dissolve the thrombus by breaking down the fibrins and can be applied in any timeframe. The proteolytic enzymes in Krillase can breakdown any fibrous cap on any age of clot. This is
extremely useful if the patient hasn’t been able to reach an acute care center within the required 3-6 hours for tPA and TNK. Also, Krillase works in 1/10th the time dissolving complex aged clots in 3 minutes as opposed to 30 minutes thus saving more heart or brain tissue from ischemic death. Most importantly, due to the mechanism of action of Krillase, there is no chance of bleed out and it would be acceptable to use it in most patient populations, even children.
Thrombolysis Monetization Strategy:
Marizyme intends to apply for a Rare Pediatric Voucher and
complete studies for application of Krillase in children. The Rare Pediatric Disease Voucher is transferable and of the 13 or so that have been issued most have been sold to large pharmaceutical companies for $125M to $350M. We intend to complete a pediatric stroke study and license Krillase to Roche/Genentech for human use and then sell the Voucher to the highest bidder.
3. Marizyme Business Model
Quote:
We intend to follow a model of licensing out our promising technologies for individual applications to larger players who bring competitive advantages that our shareholders will benefit from including distribution, industry certification, unique market experience, brand or assistance in completing clinical studies. We intend to grant exclusive licenses to our technology either worldwide or on a larger territory basis for specific applications. In exchange we will seek ownership in our partner when feasible, milestone payments, and ongoing royalties. Our partners will be expected to make investments in the final product
and to package, market and distribute that product. We believe this approach will allow us to pursue several opportunities concurrently and we will begin with the first three applications described within this summary.
Nicholas P. DeVito, 54 – CEO Mr. DeVito
has 32 years of experience in finance, engineering and operations in a variety of industries including oil & gas, telecommunications, alternative energy, manufacturing and consumer products. Most recently he served as Director of Accounts at Synchronoss Technologies, Chief Operating Officer for Xtreme Oil & Gas (OTCBB:XTOG) successfully reorganizing the company and completing the filings to begin public trading. Mr. DeVito has served VP of Business Development and as CEO of several subsidiaries in Tellium (NASDAQ:ZHNE), a highly successful telecommunications equipment manufacturer that sold $200M of optical switching products and completed an IPO raising $400M. He consulted to several private consumer products companies acting to improve operations and grow sales. Finally, Nick spent 14 years at AT&T and Bell Laboratories. He has a BSEE and MSEE from Columbia University and an MBA in Management from New York University.
The potential market size for Krillase in Germany alone is $6 billion. The company plans to license Krillase technology as part of a wound care monetization strategy. $$$ $GBSXD $$$
Float is most likely less than 172k shares. $$$ $GBSXD $$$
Etrade had my $GBSXD shares in my account this morning. Starting Monday volume and buy sell action should be increasing. Looking for $3 to $4.5 short term until more info on Marizyme, Inc. is made known- then maybe $7 or more pps - who knows?
Yea, I've heard a lot of bad things resulting from a R/s. I trying and stay away from them. My shares and PPS changed over and I came out with a 600 dollar gain so far.
Whether or not a R/S is a good thing or a bad thing depends on the company and how they proceed after the split. Most of the splits on the OTC turn out bad.
ImO...... this R/S won't necessarily be one with a negative impact. From the DD, I feel this is going to be a very solid play over the next few months.
I'm currently bid fishing for .50's
$$$$$$$$$GBSXD (@ .542 now)$$$$$$$
Ah right! Thanks for the clarification man. I really appreciate it!
no. in a few days your shares will be in your brokerage account
35k/29 = 1206
you will have 1207 shares
yesterday your 35k shares were worth $1750
today even though you can't sell them your shares are worth $654(last pps today was .542)
anyway the pps will be going up and down over the next days, weeks, months and years.
my guess is this will easily trade @ $3 to $4.50 once they start PR'ing, 8k'ing, and filing financial reports
Yea it actually is! I hate R/S LOL. So tell me something, what if the PPS doesnt reach the 1.45, do my shares basically lay there dead?
lol. this must be your first play that conducted an r/s- after the next few r/s's you go thru you will have more of an understanding of what is going on post split. welcome to pinkyland.
That sucks! So I have 35K shares just sitting there making nothing!
the only gain you will get is if the pps is over $1.45 when you get your shares. $1.45 was the effective pps pre-split
yesterday the pps closed @ .05 - after the close there was a 1 for 29 r/s
29 x .05 = $1.45
Will I still get that gain?
Not sure I understand
nope. pps needs to be @ 1.45 to = yesterdays closing pps
takes a few days for the brokers to switch over
I'm not making anything with the GBSXD stock at 197%
I was wondering if someone can help me out with something.
I have 35K shares, and they still say GBSX with the PPS at 0. Why didnt these shares switch to GBSXD? Thanks guys!
Seems like it’s a done deal already:
funnyG986 Member Level Tuesday, 03/20/18 09:39:36 AM
Re: RickKayne post# 4 0
Post # of 218
GBSX name change and merge in showing, new company name MARIZYME, INC.
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=3ZnpU8XWHML%252b4rmlz34uaA%253d%253d&nt7=0
Merge In
It seems a merger with the following biotech company
http://marizyme.com/about-us/
Anyone know when this merger is suppose to take place
Starting tomorrow float should be around 172k - o/s will be 1.1m until they issue more shares. Pps will open around $1.5 and go up from there is my guess. $GBSX
Outstanding Shares
31,929,291
Q
07/20/2018
GBSX: effective July 27,2018 GBS Enterprises Inc. will change to Marizyme Inc. and a one for 29 reverse split:
http://otce.finra.org/DLSymbolNameChanges
I am collecting here and there in the bid... got. quiet allot allready.... but imo Boom coming at Dome Stage
opps. i thought you posted someone sold 'me' .06's - but it was someone sold 'more' 6's lol
Yes, for someone! Unfortunately it wasn't me.
Someone sold more into the bid at EOD. I am hoping we will get some updates soon. Could move back up just as easily.
Sounds good! Thanks
if anything comes up i will post on this board
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
359
|
Created
|
02/17/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |